Company / Accounts Receivable
Ligand Pharmaceuticals, Inc. Accounts Receivable History
FY2018-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Accounts Receivable
$59.6M
FY2025
5-year range
$30.4M / $85.5M
FY2021-FY2025
Trend
+55.3%
vs FY2024
Sector context
#66 of 113
Health Care
What the data says
At $60M, Ligand Pharmaceuticals, Inc.'s accounts receivable ranks #66 of 113 in the Health Care sector. Accounts Receivable has increased for 3 consecutive years, from $30M in FY2022 to $60M in FY2025.
Based on SEC 10-K filings.
$60M in FY2025 with a 5-year CAGR of +1.0%.
Improved from $33M to $60M over the past 2 years.
Health Care sector context is included.
Accounts Receivable over time
Growth rates
- 3-Year CAGR
- +25.1%
- 5-Year CAGR
- +1.0%
- 10-Year CAGR
- -
Sector benchmark
#66 of 113 in Health CareTop 58% of 113This company $59.6M Sector average $1.1B
▼
-94.8% below sector average
Key checks
Key Insights
- Ligand Pharmaceuticals, Inc.'s accounts receivable has grown for 3 consecutive years.
- 5-year CAGR of +1.0%, indicating consistent growth.
- In FY2025, accounts receivable increased 55.3% year-over-year.
- Ranks #66 out of 113 companies in the Health Care sector.
Company context
Key Data Points
- Low earnings quality (accrual-heavy earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Accounts ReceivableValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $59.6M | +55.3% |
| FY2024 | $38.4M | +16.6% |
| FY2023 | $32.9M | +8.2% |
| FY2022 | $30.4M | -64.4% |
| FY2021 | $85.5M | +50.3% |
| FY2020 | $56.8M | +87.1% |
| FY2019 | $30.4M | -45.6% |
| FY2018 | $55.9M | - |
| FY2017 | - | - |
| FY2016 | - | - |
As of FY2025 · SEC 10-K · Updated Feb 28, 2026